<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053932</url>
  </required_header>
  <id_info>
    <org_study_id>DREPAGREFFE2</org_study_id>
    <nct_id>NCT05053932</nct_id>
  </id_info>
  <brief_title>Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Sickle Cell Anemia</brief_title>
  <acronym>DREPAGREFFE2</acronym>
  <official_title>Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Children With Sickle Cell Anemia ( DREPAGREFFE-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre National de la Recherche Scientifique, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Etablissement Français du Sang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present observational study is to remotely reevaluate the cohort of 67&#xD;
      sickle cell patients with transcranial Doppler-detected cerebral vasculopathy included in the&#xD;
      national &quot;Sickle Cell Transplant&quot; protocol and whose 1- and 3-year results were published in&#xD;
      JAMA (Journal of the American Medical Association) in 2019 and in BHJ in 2020.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present observational study has the objective to reevaluate at distance the cohort of 67&#xD;
      children with sickle cell anemia enrolled in the &quot;Drepagreffe&quot;trial because of cerebral&#xD;
      vasculopathy detected by transcranial Doppler. Results at 1 and 3 years were reported in JAMA&#xD;
      in 2019 in BHJ in 2020. This trial was the first worldwide prospective study comparing&#xD;
      transplantation to standard care in sickle cell disease. Velocities were highly significantly&#xD;
      more reduced with a higher proportion of patients with normalized velocities and better&#xD;
      quality of life after transplantation than on standard care. Despite a trend to a better&#xD;
      ischemic lesions outcome at 3 years, the difference was not significant and cognitive&#xD;
      performances were not different between both groups. The biologic study only assessed at&#xD;
      enrollment and 1-year showed lower levels of Ang-2 and HGF (hepatocyte growth factor) after&#xD;
      transplant and a significant and independent association between Doppler normalization&#xD;
      probability with low Ang-2 and BDNF (brain-derived neurotrophic factor) levels.The aim of the&#xD;
      present study is to reassess at 9-10 years this cohort with grants allowing to reevaluate&#xD;
      cognitive functioning and hypoxia/angiogenic factors not realized in the systematic cohort&#xD;
      follow-up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long term evolution (at 9-10 years) of Ischemic lesion on brain magnetic resonance imaging 10-year measurement of ischemic lesion on magnetic resonance imaging</measure>
    <time_frame>within 6 months of inclusion</time_frame>
    <description>The MRI-scores, ranging from 0 (best outcome) to 10 (worst outcome), are obtained by adding up the ischemic lesion scores from the left and right sides, i.e., 3 for territorial or 2 for border zone (cortical and subcortical), 1 for white matter and 1 for basal ganglia infarcts and 0 if absent on each side.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long term evolution (at 9-10 years) of arterial stenosis on cerebral and cervical magnetic resonance angiography</measure>
    <time_frame>within 6 months of inclusion</time_frame>
    <description>The MRA stenosis-scores, ranging from 0 (best outcome) to 32 (worst outcome) are defined as the weighted sums over the 8 assessed cerebral arteries, as 0 if no stenosis, 1 if mild stenosis (25-49%), 2 if moderate stenosis (50-74%), 3 if severe stenosis (75-99%), and 4 if occlusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term evolution (at 9-10 years) of cognitive performance</measure>
    <time_frame>within 6 months of inclusion</time_frame>
    <description>Full Scale Intelligence Quotient (40= worst outcome, 160= best outcome) is measured by Wechsler Intelligence Scale for Children -Fourth Edition (WISC-4) for children 7-16 years of age and by WAIS-3 (Weschler Adult Intelligence Scale-3) for patients older than 16 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term evolution (at 9-10 years) of quality of life</measure>
    <time_frame>within 6 months of inclusion</time_frame>
    <description>Quality of life assessment is collected using the French version of the Pediatric Quality of Life Inventory Generic Core Scale (PedsQLTM 4.0 generic core scales) (physical, emotional, social, school items) (0= worst outcome, 100= best outcome) via self-report and parent proxy-report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution at 9-10 years of factors of hypoxia and oxidative stress</measure>
    <time_frame>within 6 months of inclusion</time_frame>
    <description>Assessment on plasma Phosphatidyl-serine expression VEGF, Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2),EPO, HIF-1, BDNF, PDGF-AA</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Cerebral Ischemia</condition>
  <condition>Stenosis</condition>
  <arm_group>
    <arm_group_label>Patients included in Drepagreffe 1 study (NCT01340404)</arm_group_label>
    <description>biological collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood collection</intervention_name>
    <description>blood collection</description>
    <arm_group_label>Patients included in Drepagreffe 1 study (NCT01340404)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  One blood sample for the checking of anti-erythroid alloimmunisation and exposition of&#xD;
           phosphatidyl-serine.&#xD;
&#xD;
        -  DNA and plasma will be frozen, stored for hypoxia-factors/angiogenesis and nitroso-redox&#xD;
           stress analysis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Population concerned 67 patients included in 2011-2013 in the DREPAGREFFE protocol [NCT&#xD;
        01340404]&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient of legal age or minor who participated in the DREPAGREFFE research protocol&#xD;
             [NCT 01340404] between December 2010 and June 2013,&#xD;
&#xD;
          -  Having read and understood the information letter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Patient deceased&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Camille JUNG, MD</last_name>
    <phone>01 57 02 22 68</phone>
    <phone_ext>+33</phone_ext>
    <email>camille.jung@chicreteil.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Françoise BERNAUDIN, MD</last_name>
      <email>francoise.bernaudin@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Francoise BERNAUDIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corinne GUITTON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie PETRAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suzanne VERLHAC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marianne De MONTALEMBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra GAUTHIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle THURET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine PAILLARD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

